title: Complete remission at laparotomy: still a gold standard in ovarian cancer?
authors.forename: J P
authors.initials: JP
authors.lastname: Neijt
authors.forename: W W
authors.initials: WW
authors.lastname: ten Bokkel Huinink
authors.forename: M E
authors.initials: ME
authors.lastname: Van der Burg
authors.forename: A T
authors.initials: AT
authors.lastname: van Oosterom
mesh_terms: D006585:Altretamine / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007813:Laparotomy; D008727:Methotrexate / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011897:Random Allocation
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D006585:Altretamine; D005472:Fluorouracil; D008727:Methotrexate